Clinical trial
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic…
NCT00327743 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00327743 |
|---|---|
| Title | Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer |
| Official title | A Dose-escalating, Multicenter, Single Arm, Open-Label Study of XRP9881 in Combination With Capecitabine (Xeloda), in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and Taxane Therapy |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Cancer |
| Intervention type | Drug |
| Interventions | larotaxel, capecitabine |
| Enrollment | 34 |
| Start date | Aug 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | May 18, 2006 |
| Last update posted | May 18, 2016 |
| Countries | France, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: